[144] NuSkin Enterprises, Inc. SEC Filing

Rhea-AI Filing Summary

Nu Skin Enterprises (NUS) Form 144 filing reports a proposed sale of 9,046 shares of Common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $109,635.71. The shares represent restricted stock that vested under the issuer's registered plan on 04/24/2012 (4,046 shares) and 05/24/2018 (5,000 shares), with cash payment recorded on the respective vesting dates. The filer states there were no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: Routine insider sale notice for 9,046 shares totaling $109,636; immaterial relative to outstanding shares.

The filing documents a Rule 144 notice for the proposed sale of 9,046 common shares via Morgan Stanley Smith Barney on the NYSE, stemming from previously vested restricted stock grants from 2012 and 2018. The aggregate value reported is $109,635.71 and there were no sales in the prior three months. Given the issuer's outstanding share count of 49,497,715, the size of this proposed sale is de minimis and unlikely to affect valuation or signal material changes in company operations.

Corporate Governance Expert

TL;DR: Standard compliance filing under Rule 144 documenting disposition of vested restricted shares; contains required seller attestation.

The notice follows Rule 144 requirements by identifying the broker, share count, acquisition dates, and nature of acquisition (restricted stock vesting under a registered plan). It includes the seller's attestation regarding material undisclosed information. This filing appears procedural and compliant with disclosure norms; it does not disclose any governance actions or unusual insider activity beyond a planned sale of vested shares.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9046	109635.71	49497715	08/29/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/24/2012	Restricted stock vesting under a registered plan	Issuer			4046	04/24/2012	Cash
Common	05/24/2018	Restricted stock vesting under a registered plan	Issuer			5000	05/24/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Nu Skin Enterprises' (NUS) Form 144 report?

The filing reports a proposed sale of 9,046 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $109,635.71.

When were the securities being sold originally acquired?

The securities were acquired as restricted stock that vested on 04/24/2012 (4,046 shares) and 05/24/2018 (5,000 shares), with cash paid on those dates.

Does the Form 144 show other sales by this person in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

Who is the broker handling the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filer assert any undisclosed material information about the issuer?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.